PCM
PVLA

Penn Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Penn Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$841K Buy
+5,506
New +$668K 0.05% 128

Other funds holding PVLA

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
CAM
Clio Asset Management Charlottesville, Virginia $126M AUM 16.01% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $4.05B AUM 19.01% 1-Year Est. Return

Penn Capital Management's PVLA Position: Q2 2026 in Review

Penn Capital Management opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 5,506 shares worth $841K. The stake represents 0.05% of the portfolio and ranks #128 among its holdings.

32 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Penn Capital Management held 5,506 shares of Palvella Therapeutics worth $841K as of Q2 2026.
  • Palvella Therapeutics was a new Penn Capital Management position in Q2 2026.
  • Palvella Therapeutics made up 0.05% of Penn Capital Management's portfolio in Q2 2026, its #128 holding.
  • 32 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.